Abstract:Coronavirus disease 2019 (COVID-19) has brought enormous loss and interruption to human life and the global economy since the first outbreak reported in China between late 2019 to early 2020, and will likely remain a public health threat in the months and years to come. Upon infection with SARS-CoV-2, the virus that causes COVID-19, most people will develop no or mild symptoms, however, a small percentage of the population will become severely ill, require hospitalization, intensive care, and some succumb to death. The current knowledge of COVID-19 disease progression with worsening symptom complex implicates the critical importance of identifying patients with high clinical risk compared to those who would be at lower risk for disease control and patient management with better therapeutic output. Currently no clinical test is available that can predict risk factors and immune status change at different severity scales. The immune system plays a critical role in the defense against infectious diseases. Extensive research has found that COVID-19 patients with poor clinical outcomes differ significantly in their immune responses to the virus from those who exhibit milder symptoms. We previously developed a nanoparticle-enabled blood test that can detect the humoral immune status change in animals. In this study, we applied this new test to analyze the immune response in relation to disease severity in COVID-19 patients. From the testing of 153 COVID-19 patient samples and 142 negative controls, we detected statistically significant differences between COVID-19 patients with no or mild symptoms from those who developed moderate to severe symptoms. Mechanistic study suggests that these differences are associated with type 1 versus type 2 immune responses. We conclude that this new rapid test could potentially become a valuable clinical tool for COVID-19 patient risk stratification and management. ### Competing Interest Statement Dr. Huo reports other from Nano Discovery Inc., outside the submitted work; In addition, Dr. Huo has a patent Detection of Interaction Between an Assay Substance and Blood or Blood Components for Immune Status Evaluation and Immune Related Disease Detection and Diagnosis pending. ### Funding Statement This study is supported by intramural funding from Nano Discovery Inc. and Orlando Health. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study (OH IRB # 20.095.06) was approved by Orlando Health IRB#2. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

RNA self-blood collection enables high-frequency temporal profiling of the pre-symptomatic host immune kinetics to respiratory viral infection: a prospective cohort study

Temporal High-Resolution Atlas of Human Blood Leukocyte Composition in Response to Respiratory Virus Inoculation

Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection

Kinetics of SARS-CoV-2 infection biomarkers in a household transmission study

SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infections

High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals

Defining within-host SARS-CoV-2 RNA viral load kinetics during acute COVID-19 infection within different respiratory compartments and their respective associations with host infectiousness: a protocol for a systematic review and meta-analysis

Human SARS-CoV-2 challenge uncovers local and systemic response dynamics

Abstract 5643: Targeted RNA-seq of dried blood microsamples for convenient RNA biomarker monitoring

A One-Minute Blood Test to Monitor Immune Responses in COVID-19 Patients and Predict Clinical Risks of Developing Moderate to Severe Symptoms

A machine learning classifier using 33 host immune response mRNAs accurately distinguishes viral and non-viral acute respiratory illnesses in nasal swab samples

Proteome profiling of home-sampled dried blood spots reveals proteins of SARS-CoV-2 infections

Opportunities for Enhanced Public Health Surveillance via Molecular Detection and Sequencing of Diverse Respiratory Viruses From Self-collected SARS-CoV-2 Antigen Test Swabs

Characterization of CXCL10 as a biomarker of respiratory tract infections detectable by open-source lateral flow immunoassay

Excellent option for mass testing during the SARS-CoV-2 pandemic: painless self-collection and direct RT-qPCR

881. Saliva-Based, Extraction-Free PCR Testing For The Detection Of Key Respiratory Pathogens

Evaluation of Self-collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing via RT-PCR and Comparison of Amplicon Sequences Against Commonly Used Primers in Diagnostic Assays

Validation of an unbiased metagenomic detection assay for RNA viruses in viral transport media and plasma

Within-host evolutionary dynamics and tissue compartmentalization during acute SARS-CoV-2 infection

Blood transcriptomics analysis offers insights into variant-specific immune response to SARS-CoV-2

Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants